Anteris Technologies Global (NASDAQ:AVR) Upgraded at Barclays

Barclays upgraded shares of Anteris Technologies Global (NASDAQ:AVR) to a hold rating in a research note issued to investors on Wednesday morning,Zacks reports.

AVR has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 price objective on shares of Anteris Technologies Global in a research note on Friday, August 14th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Anteris Technologies Global currently has an average rating of “Hold” and a consensus price target of $14.00.

Anteris Technologies Global Price Performance

AVR stock opened at $6.77 on Wednesday. The company has a market cap of $659.80 million, a P/E ratio of -3.47 and a beta of 1.87. Anteris Technologies Global has a 1 year low of $3.30 and a 1 year high of $11.06. The stock’s fifty day moving average price is $8.39 and its 200-day moving average price is $8.02.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%. The firm had revenue of $1.01 million during the quarter, compared to the consensus estimate of $1.50 million. During the same period in the previous year, the firm earned ($0.58) EPS. As a group, analysts expect that Anteris Technologies Global will post -1.21 earnings per share for the current year.

Insider Activity at Anteris Technologies Global

In related news, major shareholder L1 Capital Pty Ltd acquired 272,695 shares of Anteris Technologies Global stock in a transaction dated Tuesday, October 6th. The stock was purchased at an average cost of $7.18 per share, for a total transaction of $1,957,950.10. Following the purchase, the insider directly owned 6,358,271 shares of the company’s stock, valued at approximately $45,652,385.78. This trade represents a 4.48% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders acquired 1,554,730 shares of company stock valued at $11,694,513 and sold 3,008,459 shares valued at $25,243,576. 4.50% of the stock is owned by company insiders.

Institutional Trading of Anteris Technologies Global

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Anteris Technologies Global in the 2nd quarter worth approximately $56,846,000. Nantahala Capital Management LLC purchased a new position in Anteris Technologies Global during the second quarter valued at approximately $33,325,850. ADAR1 Capital Management LLC purchased a new position in Anteris Technologies Global during the second quarter valued at approximately $30,979,000. Perceptive Advisors LLC lifted its holdings in Anteris Technologies Global by 104.4% during the first quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock valued at $19,011,000 after purchasing an additional 1,750,000 shares in the last quarter. Finally, Militia Capital Management LLC bought a new position in shares of Anteris Technologies Global in the first quarter worth approximately $3,663,000.

Key Anteris Technologies Global News

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: L1 Capital expanded its AVR stake. The major shareholder purchased 272,695 shares for approximately $1.96 million at an average price of $7.18, increasing its position by 4.48% to 6.36 million shares. The purchase follows additional buying totaling more than 1.2 million shares in early October, signaling continued confidence from a significant investor. SEC filing on L1 Capital’s AVR purchase
• Positive Sentiment: Institutional ownership has grown. BlackRock, ADAR1 Capital Management, Bank of New York Mellon and other investment firms recently established or increased positions in AVR. Such buying may improve investor sentiment and provide additional institutional support, although the positions were reported from earlier quarters.
• Neutral Sentiment: Barclays initiated coverage at Hold/Equal Weight. The rating gives AVR additional analyst visibility but indicates limited conviction for near-term outperformance. Other analysts remain divided, with an average rating of Hold and an average price target of $14. Barclays AVR rating report
• Neutral Sentiment: Short-interest data showed no current short position. The latest report listed short interest at zero shares and a zero-day days-to-cover ratio. This does not indicate meaningful short-squeeze potential, though the figure may reflect a reporting or data-timing issue.
• Negative Sentiment: Employee equity-plan expansion could create dilution concerns. Anteris expanded unquoted equity under its employee incentive plan. Potential future share issuance may weigh on the stock, particularly because the clinical-stage company remains unprofitable. Anteris employee incentive-plan announcement
• Negative Sentiment: Financial results remain weak. Anteris recently reported a larger-than-expected quarterly loss and revenue below forecasts. Analysts expect a full-year loss, keeping execution, clinical progress and future financing as key risks.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.